Prospective real world data of an ongoing post-authorization safety study on idelalisib in patients with CLL and refractory FL.

18. Oktober 2018

Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Ramroth, H., Rummel, M., 2018.

Oncol Res Treat 41 (suppl 4) (P534), 173.